ASX Announcements

Presentation - Reducing Progression Rate of Age-Related Macular Degeneration

ASX Announcement General AlphaRET

21 Dec, 2021

Cancel - Proposed Issue of Securities

ASX Announcement General

30 Nov, 2021

Notification of Issue of Securities 2

ASX Announcement General

30 Nov, 2021

Notification of Issue of Securities

ASX Announcement General

30 Nov, 2021

Notification of Issue, Conversion or Payment up of Unquoted Equity Securities

ASX Announcement General

30 Nov, 2021

Appendix 3Z Final Director's Interest Notice

ASX Announcement General

25 Nov, 2021

2021 Annual General Meeting Voting Results

ASX Announcement General

25 Nov, 2021

Presentation - Annual General Meeting 2021

ASX Announcement General

24 Nov, 2021

Withdrawal of AGM Resolutions 2,4,6,7,8 and 9 From Notice of Meeting

ASX Announcement General

24 Nov, 2021

Resignation of Mr Alex Sundich

ASX Announcement General

24 Nov, 2021

Jobkeeper Payments Notification

ASX Announcement General

11 Nov, 2021

Clarification of Escrow Details

ASX Announcement General

5 Nov, 2021

US Government Stimulus Loan Forgiven

ASX Announcement General

26 Oct, 2021

Notice of Annual General Meeting

ASX Announcement General

21 Oct, 2021

5-Year Efficacy and Safety of iTrack™ to be Spotlighted at ESCRS 2021

ASX Announcement General iTrack Molteno3 AlphaRET

7 Oct, 2021

EYE FY21 Date of AGM & Closing Date for Director Nominations

ASX Announcement General iTrack Molteno3 AlphaRET

30 Sep, 2021

Nova Eye Medical to Present at ASX Small to Mid-Cap Conference

ASX Announcement General iTrack Molteno3 AlphaRET

10 Sep, 2021

Closure of Share Sale Facility for Unmarketable Parcels

ASX Announcement General

3 Sep, 2021

Proposed issue of securities

ASX Announcement General

26 Aug, 2021

Nova Eye Medical Acquires Key Glaucoma Patents to Drive New Product Expansion

ASX Announcement General iTrack

26 Aug, 2021

Nova Eye Medical Reports 25% Growth in Glaucoma Device Sales for the 2021 Fiscal Year

ASX Announcement General

19 Aug, 2021

Appendix 4E

ASX Announcement General

19 Aug, 2021

Appendix 4G & Corporate Governance Statement

ASX Announcement General

19 Aug, 2021

Application for Quotation of Securities

ASX Announcement General

18 Aug, 2021

Proposed Issue of Securities

ASX Announcement General

18 Aug, 2021

Notice of Upcoming Investor Call – Full Year (FY21) Results

ASX Announcement General

11 Aug, 2021

Notice of change of interests of substantial holder

ASX Announcement General

29 Jul, 2021

Nova Eye Medical FY21 Trading Update

ASX Announcement General

20 Jul, 2021

NOTICE OF SHARE SALE FACILITY FOR HOLDERS OF LESS THAN MARKETABLE PARCELS

ASX Announcement General

15 Jul, 2021

Nova Eye Establishes Share Sale Facility for Unmarketable Parcels

ASX Announcement General

15 Jul, 2021

Nova Eye Medical Files IDE Application with the FDA to Commence a Pivotal Study in the US Evaluating 2RT

ASX Announcement AlphaRET

5 Jul, 2021

2RT® Featured at the 2021 Meeting of the Association for Research in Vision and Ophthalmology

ASX Announcement General AlphaRET

3 May, 2021

Notice of Change of Interests of Substantial Holder

ASX Announcement General

30 Apr, 2021

First Patient Enrolled in MAGIC Clinical Trial for Glaucoma

ASX Announcement General iTrack

30 Apr, 2021

Five-Year Post-LEAD Review Shows Improvement in 2RT® Treatment Benefits for iAMD

ASX Announcement General AlphaRET

5 Mar, 2021

Clinical Trial to Assess Efficacy and Safety of iTrack™ in the Treatment of Mild to Moderate Glaucoma

ASX Announcement General iTrack

2 Mar, 2021

First Half FY2021 Accounts

ASX Announcement General

25 Feb, 2021

1HFY21: Growth in Glaucoma Surgical Devices Segment Despite Pandemic

ASX Announcement General

25 Feb, 2021

Notice of Upcoming Investor Call – First Half FY21 Results

ASX Announcement General

18 Feb, 2021

For investor enquires please contact:

Dr. Tom Duthy
Nova Eye Medical Limited
W +61 402 493 727
tduthy@nova-eye.com

This website uses cookies to ensure you get the best experience on our website.
The cookies do not store any personalised information. Learn More